Alzheimer's disease under the mask of stroke

Will your doctor learn anything from this? Because YOU have to worry about it. 

Your chances of getting dementia.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

5. Parkinson’s Disease May Have Link to Stroke March 2017

 The research here:

Alzheimer's disease under the mask of stroke

Болезнь Альцгеймера под маской инсульта.  Neurology, Neuropsychiatry, Psychosomatics , Volume 8(2) , Pgs. 100-106.

NARIC Accession Number: I245728.  What's this?
Author(s): Naumenko A.A; Vakhnina N.V.
Publication Year: 2016.
Abstract: This paper discusses the epidemiology, risk factors, and pathogenesis of poststroke cognitive impairments (CIs), current methods for its diagnosis, as well as symptomatic and pathogenetic treatment. CIs are common in poststroke patients. The basis for this condition is frequently a neurodegenerative process and most often Alzheimer's disease (AD). Stroke may promote the manifestation of clinically asymptomatic AD, worsen pre-stroke cognitive deficit, or merely manifest pre-stroke CIs. The most informative method for the diagnosis of poststroke CIs is a neuropsychological examination that should be made in the early poststroke period (if the patient's consciousness is clear). The most common screening tests include the Mini-Mental State Examination (the most sensitive to evaluate cognitive dysfunction in Alzheimer type dementias) and the Montreal Cognitive Assessment. Magnetic resonance imaging of the brain, positron emission tomography, cerebrospinal fluid examination, and genetic testing are used to reveal AD at its preclinical stages. Preventive measures include regular physical activity, a balanced diet, and a sufficient mental workload. The prevention of stroke and other cardiovascular diseases is also important. The major groups of drugs used to treat AD and vascular CIs are acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists. It is expedient to use glutamatergic and acetyl-cholinergic therapy earlier in patients with obvious CIs that are unassociated with emotional problems and disturbance of consciousness. Akatinol memantine is a drug that can be regarded not only as a symptomatic but also a pathogenetic agent.
Descriptor Terms: Alzheimer's disease, Cognition, Cerebrovascular disease, Dementia, Drugs, Stroke.
Language: Russian
Geographic Location(s): Europe, Russia.

Can this document be ordered through NARIC's document delivery service*?: Request Information.
Get this Document: https://nnp.ima-press.net/nnp/article/view/616/566.

Citation: Naumenko A.A, Vakhnina N.V. (2016). Alzheimer's disease under the mask of stroke.  Болезнь Альцгеймера под маской инсульта.  Neurology, Neuropsychiatry, Psychosomatics , 8(2), Pgs. 100-106. Retrieved 11/22/2019, from REHABDATA database.